- 不限
- 2021-12-10 [星期五]
- 2021-12-11 [星期六]
- 2021-12-12 [星期日]
- 不限
- 乙肝治愈转化医学研究 Translational study for functional cure of chronic HBV infection
- 肝癌及门脉高压治疗 Treatment of liver cancer and portal hypertension
- 肝衰竭、人工肝、重症感染 Liver failure, artificial liver, severe infection
- 肿瘤免疫治疗及转化研究 Tumor Immunotherapy and Translational Research
- 精准医学高峰论坛 Precision Medicine Summit Forum
- 国际消除病毒性肝炎论坛 International Forum on Elimination of Viral Hepatitis
- 新药研发热点 New drug research and development hotspots
- 中法肝病论坛：肝病无创诊断技术最新进展及应用 Sino-French Liver Diseases Forum：Advancement & Application of Non-invasive Diagnostic Technology
- 传染病国家级平台学科建设高峰论坛 National Platform for Discipline Construction of Infectious Diseases Summit Forum
- 介入专场 Intervention Session
- 医防融合：社区和MDT管理培训 Medical and prevention integration: community and MDT management training
- 不限
- 主会场（大沙龙厅） The Main Venue（Dashalong Hall）
- 大沙龙厅1 Dashalong Hall 1
- 大沙龙厅2 Dashalong Hall 2
- 大沙龙厅3 Dashalong Hall 3
2021-12-10 星期五
肝癌及门脉高压治疗 Treatment of liver cancer and portal hypertension
大沙龙厅1 Dashalong Hall 1
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 14:30-14:50 |
肝癌的免疫治疗 |
Richard S. Finn | Department of Surgery, Dumont-UCLA Liver Cancer Center |
|
Incorporating Immunotherapy into the Management of HCC |
Richard S. Finn | Department of Surgery, Dumont-UCLA Liver Cancer Center | |
| 14:50-15:10 |
实验介入学VS前沿介入技术 |
李茂全 | 同济大学附属第十人民医院 |
|
Experimental Intervention vs Frontier Intervention Technology |
Maoquan Li | Tenth People's Hospital of Tongji University | |
| 15:10-15:30 |
ACTA的研究进展及他汀类药物的临床实践带给我们的启示 |
江家骥 | 福建医科大学附属第一医院 |
|
Research progress of ACTA and the inspiration from clinical practice of statins |
Jiaji Jiang | The First Affiliated Hospital of Fujian Medical University | |
| 15:30-15:50 |
中国原发性肝癌诊疗规范 |
任正刚 | 复旦大学附属中山医院 |
|
Standards for diagnosis and treatment of primary liver cancer in China |
Zhenggang Ren | Zhongshan Hospital Red Cross Hospital |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 16:10-16:30 |
门静脉癌栓诊疗 |
程树群 | 海军军医大学第三附属医院（东方肝胆外科医院） |
|
Portal vein cancer thrombus diagnosis and treatment |
Shuqun Cheng | Eastern Hepatobiliary Surgery Hospital | |
| 16:30-16:50 |
肝癌放疗 |
曾昭冲 | 复旦大学附属中山医院 |
|
Radiotherapy for liver cancer |
Zhaochong Zeng | Zhongshan Hospital Red Cross Hospital | |
| 16:50-17:10 |
肝癌根治术 |
匡 铭 | 中山大学附属第一医院 |
|
Radical resection of liver cancer |
Ming Kuang | The First Affiliated Hospital, Sun Yat-Sen University, China | |
| 17:10-17:30 |
肝癌治疗分子标志物进展 |
刘 莉 | 南方医科大学南方医院 |
|
Progress of molecular markers in the treatment of liver cancer |
Li Liu | Nanfang Hospital, Southern Medical University |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 17:30-17:50 |
专题研讨会：卡瑞利珠单抗-肝癌免疫治疗新进展 |
陈锦章 | 南方医科大学南方医院 |
|
Symposium: Carrelizumab-New Progress in Immunotherapy of Liver Cancer |
Jinzhang Chen | Nanfang Hospital, Southern Medical University |
大沙龙厅2 Dashalong Hall 2
乙肝治愈转化医学研究 Translational study for functional cure of chronic HBV infection
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:00-10:30 |
生发中心免疫反应在乙肝治愈中的免疫调节作用 |
李咏茵 | 南方医科大学南方医院 |
|
Immunoregulatory Functions of Germinal Center Responses in Hepatitis B Cure |
Yongyin Li | Nanfang Hospital, Southern Medical University | |
| 10:30-11:00 |
《中国慢乙肝防治指南》更新看乙肝治愈 |
杨 晴 | 珠海市人民医院 |
|
Updated View of Hepatitis B Cure in the Guidelines for Prevention and Treatment of Chronic Hepatitis B in China |
Qing Yang | Zhuhai People's Hospital | |
| 11:00-11:30 |
HBsAg定量检测对慢乙肝抗病毒治疗停药的临床意义 |
周晓蕾 | 珠海市人民医院 |
|
The Clinical Significance of the HBsAg Quantitative Detection in Chronic Hepatitis B Patients fter Antiviral Therapy Withdrawal |
Xiaolei Zhou | Zhuhai People's Hospital | |
| 11:30-12:00 |
基于免疫调节策略的乙肝治愈新靶点的发现与开发应用 |
张小勇 | 南方医科大学南方医院 |
|
The New Target for Hepatitis B Cure Based on Immunoregulatory Strategies: Development and Application |
Xiaoyong Zhang | Nanfang Hospital, Southern Medical University |
肿瘤免疫治疗及转化研究 Tumor Immunotherapy and Translational Research
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 14:30-14:50 |
PRAK在肿瘤转移中的关键作用及其潜在的临床应用 |
张 毓 | 锦州医科大学 |
|
Key role of PRAK in tumor metastasis and its potential clinical application |
Yu Zhang | Life Science Institute of Jinzhou Medical University | |
| 14:50-15:10 |
靶向Nectin4/NKG2DL/FAP的超能Hi-TCR-T细胞对肝癌等实体肿瘤的临床试验研究 |
高基民 | 温州医科大学 |
|
Clinical trial study of super-powered Hi-TCR-T cells targeting Nectin4/NKG2DL/FAP on liver cancer and other solid tumors |
Jimin Gao | Wenzhou Medical University | |
| 15:10-15:30 |
肿瘤细胞免疫治疗新思路和新进展 |
罗荣城 | 广州中医药大学金沙洲医院 |
|
New ideas and progress in tumor cell immunotherapy |
Rongcheng Luo | TCM-Integrated Cancer Center of Southern Medical University | |
| 15:30-15:50 |
γδT细胞治疗的临床应用与未来 |
尹芝南 | 暨南大学生物医学转化研究院 |
|
Clinical application and the future of γδT cell therapy |
Zhinan Yin | Jinan University |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 16:10-16:30 |
从豪猪信号通路的分子靶点到肝癌的辅助诊断 |
吴 健 | 复旦大学基础医学院 |
| Jian Wu | Zhongshan Hospital Red Cross Hospital | ||
| 16:30-16:50 |
肝脏再生过程中基因调节网络的时空动态变化 |
Miguel A. Esteban | Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences |
|
Spatio-temporal dynamics of gene regulation during liver regeneration |
Miguel A. Esteban | Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences | |
| 16:50-17:10 |
HBV感染和HBV相关HCC的个体化T细胞治疗 |
Antonio Bertoletti | 新加坡杜克大学 |
|
Personalized T cell therapy in HBV infection and HBV-related HCC |
Antonio Bertoletti | Duke-NUS Medical School, Singapore | |
| 17:10-17:30 |
治愈HBV的免疫疗法的机遇和挑战 |
Ulrike Protzer | 德国慕尼黑亥姆霍兹中心和慕尼黑工业大学病毒研究院 |
|
Opportunities and challenges of immunotherapeutic approaches of HBV cure |
Ulrike Protzer | Institute of Virology, Technical University of Munich, Germany |
肝衰竭、人工肝、重症感染 Liver failure, artificial liver, severe infection
大沙龙厅3 Dashalong Hall 3
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 14:30-14:50 |
重症肝病短期预后的精准预测及临床应用 |
郑 敏 | 浙江大学医学院附属第一医院 |
|
Accurate prediction and clinical application of short-term prognosis of severe liver disease |
Min Zheng | The First Affiliated Hospital of Medical School of Zhejiang University | |
| 14:50-15:10 |
重症肝病的分层诊断与管理 |
李 海 | 上海交通大学医学院附属仁济医院 |
|
Hierarchical diagnosis and management of severe liver disease |
Hai Li | Renji Hospital | |
| 15:10-15:30 |
治疗重症肝病的重要有效成分及临床验证 |
王宪波 | 首都医科大学附属北京地坛医院 |
|
The important active ingredients and clinical verification for the treatment of severe liver disease |
Xianbo Wang | Beijing Ditan Hospital Capital Medical University | |
| 15:30-15:50 |
重症酒精性肝病的诊疗进展 |
高沿航 | 吉林大学第一医院 |
|
Progress in diagnosis and treatment of severe alcoholic liver disease |
Yanhang Gao | The First Buthune Hospital of Jilin University |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 16:10-16:30 |
HBV-ACLF诊断中国标准预后模型进入2.0时代 |
李 君 | 浙江大学医学院附属第一医院 |
|
Development of a simplified COSSH-ACLF II score for prognosis of HBV-ACLF |
Jun Li | The First Affiliated Hospital, College of Medicine, Zhejiang University | |
| 16:30-16:50 |
肝衰竭的基因多态性与免疫致病机制 |
邓国宏 | 中国人民解放军陆军军医大学第一附属医院 |
|
Genetic polymorphisms of liver failure and immune pathogenesis |
Guohong Deng | The Southwest Hospital of AMU | |
| 16:50-17:10 |
慢加急性肝衰竭的临床试验与进展 |
Rajiv Jalan | 英国伦敦大学学院肝病研究所 |
|
Clinical trials and progress in ACLF |
Rajiv Jalan | Institute for Liver and Digestive Health, UCL Medical School |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 17:10-17:30 |
专题研讨会：肝衰竭血液净化诊疗进展 |
陈金军 | 南方医科大学南方医院 |
|
Symposium: Advances in the Diagnosis and Therapy of Blood Purification for Liver Failure |
Jinjun Chen | Nanfang Hospital, Southern Medical University |
2021-12-11 星期六
精准医学高峰论坛 Precision Medicine Summit Forum
主会场（大沙龙厅） The Main Venue（Dashalong Hall）
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 08:00-08:30 |
视频播放 |
||
|
Video |
|||
| 08:30-08:35 |
参会嘉宾介绍 |
||
|
|
|||
| 08:35-08:40 |
致辞 |
陆骊工 | 广州市第一人民医院 |
|
Speech |
Ligong Lu | GuangZhou First People's Hospital | |
| 08:40-08:45 |
致辞 |
侯金林 | 南方医科大学南方医院 |
|
Speech |
Jinlin HOU | Nanfang Hospital, Southern Medical University | |
| 08:45-08:50 |
致辞 |
孙炳刚 | 广东省精准医学应用学会副会长 |
|
Speech |
Binggang Sun | ||
| 08:50-08:55 |
致辞 |
杨希忠 | 中国肝炎防治基金会 |
|
Speech |
Xizhong Yang | Chinese Foundation for Hepatitis Prevention and Control | |
| 08:55-09:00 |
全体合影 |
||
|
Group Photo |
|||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 09:00-09:20 |
肝癌综合诊疗的研究进展及设想 |
陆骊工 | 广州市第一人民医院 |
| Ligong Lu | GuangZhou First People's Hospital | ||
| 09:20-09:40 |
彩虹计划：肝癌早筛和早诊进展 |
侯金林 | 南方医科大学南方医院 |
|
Rainbow Project: Progress in Screening and Diagnosis Strategy for Hepatocellular Carcinoma in Early Stage |
Jinlin HOU | Nanfang Hospital, Southern Medical University | |
| 09:40-10:00 |
发现IL-27在脂肪细胞中的新功能 |
尹芝南 | 暨南大学生物医学转化研究院 |
|
Discovery in the Novel Function of IL-27 on Adipocytes |
Zhinan Yin | Jinan University | |
| 10:00-10:20 |
肝病微生态 |
李兰娟 | 浙江大学 |
|
Liver disease microbiome |
Lanjuan Li | ||
| 10:20-10:40 |
蛋白质组学驱动的精准医学 |
贺福初 | 国家蛋白质科学中心（北京） |
|
Proteomics-driven precision medicine |
Fuchu He | ||
| 10:40-11:00 |
重症感染病细胞治疗进展 |
王福生 | 中国人民解放军总医院第五医学中心 |
|
Progress in cell therapy for severe infections |
Fusheng Wang | The Fifth Medical Center of PLA General Hospital |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 11:00-11:20 |
应检尽检：从新冠到消除肝炎 |
张文宏 | 复旦大学附属华山医院 |
|
Full test of the COVID-19 and elimination of hepatitis |
Wenhong ZHANG | Huashan Hospital Fudan University | |
| 11:20-11:40 |
亚太肝病学会乙肝重新激活新指南解读 |
廖家杰 | Humanity & Health Medical Group/The 5th Medical Centre of Chinese PLA General Hospital |
|
Interpretation of the Asian Pacific Association for the Study of the Liver (APASL) HBV Reactivation 2021 Guideline |
George Lau | Humanity & Health Medical Group/The 5th Medical Centre of Chinese PLA General Hospital | |
| 11:40-12:00 |
亚太原发性胆汁性胆管炎指南 |
贾继东 | 首都医科大学附属北京友谊医院 |
|
The APASL Guidelines for Primary Biliary Cholangitis |
Jidong Jia | Beijing Friendship Hospital Capital Medical University |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 12:00-12:30 |
cfDNA 全基因组测序-HIFI技术在肝癌早筛中的应用及路径 |
窦晓光 | 中国医科大学附属盛京医院 |
|
Whole genome sequencing of cfDNA: The application and path of HIFI method for the early screening of HCC |
Xiaoguang DOU | Shengjing Hospital of China Medical University |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 12:30-13:00 |
专题研讨会：效力与效果兼具--全面看待韦立得临床研究与真实世界数据 |
王贵强 | 北京大学第一医院 |
|
Symposium: Combination of Efficacy and Effectiveness-A Comprehensive View of Wellide's Clinical Research and Real-World Data |
Guiqiang WANG | Peking University First Hospital | |
| 13:00-13:30 |
中文 |
李博文 | 广东品致国际会展有限公司 |
| bw li |
国际消除病毒性肝炎论坛 International Forum on Elimination of Viral Hepatitis
大沙龙厅1 Dashalong Hall 1
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:30-13:45 |
三联消除艾滋病毒、梅毒和乙肝母婴传播的综合方法:来自世卫组织的视角 |
Morkor Newman | 世界卫生组织总部 |
|
Integrated approach for triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B: WHO perspective |
Morkor Newman | WHO Headquarter | |
| 13:45-14:00 |
艾滋病的综合治疗 |
卢洪洲 | 深圳市第三人民医院 |
|
Comprehensive treatment of AIDS |
Hongzhou LU | The Third People's Hospital of Shenzhen | |
| 14:00-14:15 |
消除病毒性肝炎：全球目标和战略 |
崔富强 | 北京大学公共卫生学院 |
|
Eliminating viral hepatitis: global goal and strategy |
Fuqiang Cui | PKU School of public health | |
| 14:15-14:30 |
2030年消除乙肝母婴传播：迈向没有乙肝的未来 |
Polin Chan | 世界卫生组织东南亚区 |
|
Elimination of HBV mother to child transmission by SDG2030: towards a HepB free new generation |
Polin Chan | World Health Organization South-East Asia Region | |
| 14:30-14:45 |
国际消除病毒性肝炎进展 |
梁晓峰 | 暨南大学基础医学与公共卫生学院 |
|
Progress in the international elimination of viral hepatitis |
Xiaofeng Liang | School of Medicine, Jinan University | |
| 14:45-15:00 |
中国三联消除计划：更新方案与新数据 |
王爱玲 | 中国疾病预防控制中心妇幼保健中心 |
|
Triple Elimination Program in China: updated scheme and new data |
Ailing Wang | Chinese Center for Disease Control and Prevention | |
| 15:00-15:15 |
COVID - 19对病毒性肝炎消除的影响 |
陈仲丹 | 世界卫生组织驻华代表处 |
|
Impact of COVID-19 on viral hepatitis Elimination |
Zhongdan Chen | WHO Resident Representative Office in China |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 15:30-15:45 |
中国何时实现乙肝病毒母婴零传播：模型研究 |
郑 徽 | 中国疾病预防控制中心 |
|
When will China achieve zero MTCT of HBV: Modelling study |
Hui Zheng | National Immunization Program, China CDC | |
| 15:45-16:00 |
预防母婴传播新进展：TAF - 新的选择 |
窦晓光 | 中国医科大学附属盛京医院 |
|
New progression in PMTCT: TAF- A new option |
Xiaoguang DOU | Shengjing Hospital of China Medical University | |
| 16:00-16:15 |
中国消除病毒性肝炎：成就与挑战 |
Lance Rodewald | 中国疾病预防控制中心 |
|
Elimination of Viral Hepatitis in China: Achievements and Challenges |
Lance Rodewald | National Immunization Program, China CDC | |
| 16:15-16:30 |
HBV感染免疫耐受期：治疗还是等待？ |
宁 琴 | 华中科技大学同济医学院附属同济医院 |
|
Immune-tolerance Phase of HBV Infection: Treat or Wait? |
Qin NING | Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology | |
| 16:30-16:50 |
专题研讨会：育龄期慢乙肝抗病毒治疗的全程管理 |
刘志华 | 南方医科大学南方医院 |
|
Symposium: The Whole Course Management of Antiviral Therapy for Chronic Hepatitis B in Childbearing Age |
Zhihua Liu | Nanfang Hospital, Southern Medical University | |
| 16:50-17:05 |
乙型肝炎的功能性治愈：从梦想到现实 |
王贵强 | 北京大学第一医院 |
|
Functional Cure for Hepatitis B: from dream to reality |
Guiqiang WANG | Peking University First Hospital | |
| 17:05-17:20 |
扩大乙肝抗病毒治疗适应证，进一步促进乙肝清除 |
彭 劼 | 南方医科大学南方医院 |
|
Extending indication of antiviral treatment for CHB in favor of hepatitis B elimination |
Jie Peng | Nanfang Hospital, Southern Medical University | |
| 17:20-17:35 |
小贝壳计划：实现乙肝母婴零传播 |
刘志华 | 南方医科大学南方医院 |
|
Shield Project: Towards zero MTCT of HBV |
Zhihua Liu | Nanfang Hospital, Southern Medical University | |
| 17:35-17:50 |
HBV母婴阻断全程管理相关研究进展 |
李 杰 | 北京大学医学部 |
|
Research progress on the management of mother-to-child interruption of HBV infection |
Jie Li | Peking University Health Science Center | |
| 17:50-18:05 |
母婴传播的医院-社区一体化管理:深圳宝安模式 |
王 维 | 深圳市宝安区妇幼保健院 |
|
Hospital-Community Integrated Management on MTCT: Shenzhen Baoan Model |
Wei Wang | Baoan Maternal and Child Health Hospital, Shenzhen, China |
中法肝病论坛：肝病无创诊断技术最新进展及应用 Sino-French Liver Diseases Forum：Advancement & Application of Non-invasive Diagnostic Technology
大沙龙厅2 Dashalong Hall 2
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 19:30-19:40 |
致辞 |
刘冬妮 | 澳门中华医学会理事长 |
|
Opening Speech |
Tong Nei Lau | Council Chair of Macao Medical Associations |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 19:40-20:00 |
无创检测在肝病疾病严重程度及预后评估中的价值及应用 |
谢 青 | 上海交通大学医学院附属瑞金医院 |
|
The Value and Application of Non-invasive Tests in Evaluation of Liver Disease Severity and Prognosis |
Qing Xie | Ruijin Hospital, School of Medicine, Shanghai Jiaotong University | |
| 20:00-20:20 |
无创检测在临床实践中的应用 |
Laurent Castéra | 法国巴黎大学 |
|
Use of Non-Invasive Tests in Clinical Practice |
Laurent Castéra | University of Paris | |
| 20:20-20:40 |
非肝硬化性门脉高压诊断进展 |
贾继东 | 首都医科大学附属北京友谊医院 |
|
Advancement in Diagnosis of Non-cirrhotic Portal Hypertension |
Jidong Jia | Beijing Friendship Hospital Capital Medical University | |
| 20:40-21:00 |
基于肝脏硬度测量的无创检测最新技术开发 |
Laurent Sandrin | 法国爱科森 |
|
Latest Technological Developments of Non-Invasive Tests Based on Liver Stiffness Measurement |
Laurent Sandrin | Echosens | |
| 21:00-21:20 |
FibroScan在社区筛查中的作用 |
颜华东 | 树兰（杭州）医院有限公司 |
|
The clinical utility of FibroScan in community screening |
Huadong Yan | Shulan（Hangzhou） Hospital |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 21:20-21:30 |
总 结 |
侯金林 | 南方医科大学南方医院 |
|
Closing Speech |
Jinlin HOU | Nanfang Hospital, Southern Medical University |
新药研发热点 New drug research and development hotspots
大沙龙厅3 Dashalong Hall 3
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:30-13:45 |
DILI研究进展和诊疗中应注意的问题 |
陈成伟 | 中国人民解放军海军第九〇五医院 |
|
Research progress of DILI and issues needing attention in diagnosis and treatment |
Chengwei Chen | 905 Hospital of PLA Navy | |
| 13:45-14:00 |
乙肝新药研发的热点问题 |
牛俊奇 | 吉林大学第一医院 |
|
Hot issues in research and development of new hepatitis B drugs |
Junqi NIU | The first hospital of Jilin University | |
| 14:00-14:15 |
乙肝受体相关抗体药物 |
李文辉 | 北京生命科学研究所 |
|
Hepatitis B Receptor Related Antibody Drugs |
Wenhui LI | National Institute of Biological Sciences, Beijing | |
| 14:15-14:30 |
乙肝RNA药物研发思考 |
吴 旻 | 安力高医药（上海）有限公司 |
|
Thoughts on development of hepatitis B RNA drugs |
Min Wu | Aligos Therapeutics | |
| 14:30-14:45 |
乙肝新药联合治疗的设计和策略 |
贾继东 | 首都医科大学附属北京友谊医院 |
|
Design and strategy of new hepatitis B drug combination therapy |
Jidong Jia | Beijing Friendship Hospital Capital Medical University | |
| 14:45-15:00 |
乙肝标志物在新药研发的价值 |
鲁凤民 | 北京大学基础医学院 |
|
Value of hepatitis B markers in the development of new drugs |
Fengmin LU | School of basic medicine Peking University | |
| 15:00-15:15 |
靶向细胞凋亡通路新药转化研究与开发 |
YANG DAJUN | 亚盛医药 |
| Dajun Yang |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 15:30-15:45 |
NASH中国和国外临床研究 |
魏 来 | 清华大学北京清华长庚医院 |
|
NASH clinical research in China and abroad |
Lai WEI | Beijing Tsinghua Changgung Hospital | |
| 15:45-16:00 |
门脉高压新药研发挑战和机遇 |
王建华 | 广州力鑫生物科技有限公司 |
|
The research and development of new drugs for portal hypertension：Challenge and opportunities |
Jianhua Wang | Guangzhou Lixin Pharmaceutical Biotechnology | |
| 16:00-16:15 |
肝纤维化的定量诊断 |
汪 艳 | 南方医科大学 |
|
Quantitative diagnosis of liver fibrosis |
Yan Wang | Southern Medical University | |
| 16:15-16:30 |
cccDNA代谢池和新药研发 |
孙 剑 | 南方医科大学南方医院 |
|
cccDNA metabolic pool and new drug development |
Jian SUN | Nanfang Hospital, Southern Medical University | |
| 16:30-16:45 |
放射性粒子增敏剂的研制 |
张福君 | 中山大学肿瘤防治中心 |
|
Development of radioactive particle sensitizer |
Fujun Zhang | Tumor Radioactive Particle Innovation Center | |
| 16:45-17:00 |
聚焦乙肝功能性治愈：新靶点新策略 |
黄 琦 | 华辉安健（北京）生物科技有限公司 |
|
Focus on the functional cure of hepatitis B: new targets and new strategies |
Qi Huang | Huahui Anjian (Beijing) Biotechnology | |
| 17:00-17:15 |
肝脏疾病中的AI数字病理学——提高对病理生物学和治疗应答的认识 |
Nikolai Naoumov | London, UK |
|
AI digital pathology in liver diseases – improved understanding of pathobiology and treatment response |
Nikolai Naoumov | London, UK | |
| 17:15-17:30 |
肝脏疾病中的ALBI评分 |
Philip Johnson | 利物浦大学 |
|
ALBI score in liver disease |
Philip Johnson | University of Liverpool | |
| 17:30-17:45 |
IAP抑制剂清除HBV感染的临床前研究 |
张小勇 | 南方医科大学南方医院 |
|
Preclinical study of IAP inhibitor to clear HBV infection |
Xiaoyong Zhang | Nanfang Hospital, Southern Medical University |
2021-12-12 星期日
大沙龙厅1 Dashalong Hall 1
介入专场 Intervention Session
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 09:00-09:20 |
三氧医学在肝病治疗中的应用 |
何晓峰 | 南方医科大学南方医院 |
|
Application of Ozone Medicine in the Treatment of Liver Diseases |
Xiao-Feng He | Nanfang Hospital, Southern Medical University, China | |
| 09:20-09:40 |
肝癌合并门静脉癌栓的介入治疗策略 |
朱康顺 | 广州医科大学附属第二医院 |
|
Interventional therapy strategy for liver cancer with portal vein tumor thrombus |
Kang-Shun Zhu | The Second Affiliated Hospital of Guangzhou Medical University, China | |
| 09:40-10:00 |
TIPS临床应用的实践与探索 |
李家平 | 中山大学附属第一医院 |
|
Practice and Exploration of Clinical Application of TIPS |
Jia-Ping Li | The First Affiliated Hospital of Sun Yat-sen University, China |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:20-10:40 |
基于临床需求的介入器具的创新 |
陈旭东 | 深圳市人民医院 |
|
Innovation of interventional devices based on clinical needs |
Xudong Chen | Shenzhen People's Hospital | |
| 10:40-11:00 |
澳门开展介入治疗的实践与分享 |
罗光辉 | Kiang Wu Hospital, Macau, China |
|
Practice and experience sharing of interventional therapy in Macau |
Guang-Hui Luo | Kiang Wu Hospital, Macau, China | |
| 11:00-11:20 |
如何在介入科开展临床研究？ |
李 勇 | 珠海市人民医院 |
|
How to carry out clinical research in the interventional department |
Yong Li | Zhuhai People's Hospital |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 11:20-11:40 |
专题研讨会：特瑞普利单抗—胆道肿瘤的免疫治疗进展 |
李文滨 | 中山大学孙逸仙纪念医院 |
|
Symposium: Teriplizumab-Progress in Immunotherapy of Biliary Tract Tumors |
Wenbin Li | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University |
医防融合：社区和MDT管理培训 Medical and prevention integration: community and MDT management training
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 13:30-13:50 |
乙型肝炎基层防治指南解读会 |
郭亚兵 | 南方医科大学南方医院 |
|
Guidelines Interpretation for Primary Prevention and Treatment of Hepatitis B |
Yabing Guo | Nanfang Hospital, Southern Medical University | |
| 13:50-14:40 |
医院社区一体化的肝炎防治 —— 高端访谈 |
||
|
Hepatitis Prevention and Treatment Based on the Integration of Hospital and Community: Top Interview
Jinlin HOU
Nanfang Hospital, Southern Medical University /
Yong Li
Zhuhai People's Hospital /
Mingyang Li
China Liver Health
|
|||
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 14:50-15:00 |
aMAP在社区肝癌筛查-早诊中的应用 |
樊 蓉 | 南方医科大学南方医院 |
|
Application of aMAP in community liver cancer screening-early diagnosis |
Rong Fan | Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China | |
| 15:00-15:10 |
中联肝健康促进中心消除丙肝行动策略 |
李明阳 | 中联肝健康促进中心 |
|
Action Strategy for Hepatitic C Elimination by China Liver Health |
Mingyang Li | China Liver Health | |
| 15:10-15:20 |
超声肝病筛查诊疗价值 |
刘广健 | 中山大学附属第六医院 |
|
Diagnostic and therapeutic importance of ultrasound liver disease screening |
Guangjian Liu | The Sixth Affiliated Hospital of Sun Yat-sen University | |
| 15:20-15:30 |
于都社区肝炎筛查模式 |
李秀华 | 于都县人民医院 |
|
Yudu Community Hepatitis Screening Model |
Xiuhua Li | Yudu people's Hospital | |
| 15:30-15:40 |
从高血压慢病管理看社区肝病筛查 |
张棉球 | 东莞市寮步镇社区卫生服务中心 |
|
View on community-level liver disease screening from management of hypertension and chronic disease |
Mianqiu Zhang | ||
| 15:40-15:50 |
乙肝肝硬化患者的抑郁和疲劳流行病学调查 |
樊 蓉 | 南方医科大学南方医院 |
|
Epidemiological Survey of Depression and Fatigue in Hepatitis B Patients with Liver Cirrhosis |
Rong Fan | Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China | |
| 15:50-16:00 |
莆田丙肝筛查 |
林国贤 | 莆田学院附属医院 |
|
Putian Hepatitis C Screening |
Guoxian Lin | The Affiliated Hospital of Putian University | |
| 16:00-16:10 |
西藏肝炎筛查经验 |
石 荔 | 西藏自治区人民医院 |
|
Hepatitis screening experience in Tibet |
Li Shi | Tibet Autonomous Region People's Hospital |
传染病国家级平台学科建设高峰论坛 National Platform for Discipline Construction of Infectious Diseases Summit Forum
大沙龙厅3 Dashalong Hall 3
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 09:00-09:15 |
慢性乙肝的临床治愈：机遇和挑战 |
王福生 | 中国人民解放军总医院第五医学中心 |
|
Functional Cure of Chronic Hepatitis B: Opportunities and Challenges |
Fusheng Wang | The Fifth Medical Center of PLA General Hospital | |
| 09:15-09:30 |
华山论剑：综合医院传染病学科的生存与发展之道 |
张文宏 | 复旦大学附属华山医院 |
|
High-end talks: survival and development of infectious diseases in general hospitals |
Wenhong ZHANG | Huashan Hospital Fudan University | |
| 09:30-09:45 |
专科医院向综合医院转型中的传染病医疗中心建设规划 |
陈效友 | 首都医科大学附属北京地坛医院 |
|
Construction plan of the contagious disease medical center in transition from a specialist hospital to a general hospital |
Xiaoyou Chen | Beijing University of Aeronautics and Astronautics | |
| 09:45-09:55 |
一体两冀学科发展的南方之路 |
孙 剑 | 南方医科大学南方医院 |
|
The Southern Way of Disciplinary Development Marked by One Focus with Two Emphases |
Jian SUN | Nanfang Hospital, Southern Medical University | |
| 09:55-10:05 |
感染病学科发展的瑞金模式 |
谢 青 | 上海交通大学医学院附属瑞金医院 |
|
The Ruijin Model for the Development of Infectious Disease Discipline |
Qing Xie | Ruijin Hospital, School of Medicine, Shanghai Jiaotong University | |
| 10:05-10:15 |
平战结合，突发传染病防控的同济经验 |
宁 琴 | 华中科技大学同济医学院附属同济医院 |
|
Tongji's experience in the prevention and control of outbreak of infectious diseases |
Qin NING | Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology | |
| 10:15-10:25 |
综合医院的感染科发展华西经验 |
唐 红 | 四川大学华西医院 |
|
West China Experience in Development of Infectious Diseases Department of General Hospital |
Hong Tang | West China Hospital of Sichuan University |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 10:35-10:45 |
专科医院转型后的内涵建设－深三经验 |
刘映霞 | 深圳市第三人民医院 |
|
Internal Development of Specialized Hospitals after Transformation——Experience of Shenzhen Third Hospital |
Yingxia Liu | The Third people's Hospital of Shenzhen | |
| 10:45-10:55 |
综合医院院长应该如何保障传染病专科的发展 |
李朝晖 | 珠海市人民医院 |
|
How Should the Comprehensive Hospital Director Guarantee the Development of Department of Infectious Diseases? |
Chaohui Li | Zhuhai People's Hospital | |
| 10:55-11:05 |
如何平衡传染病科与其它科室的协同进步 |
夏瑾瑜 | 中山大学附属第五医院 |
|
How to balance synergistic progress of the department of infectious diseases and other departments |
Jinyu Xia | The Fifth Affiliated Hospital of Sun Yat sen University |
| 时间 | 题目 | 讲者 | 单位 |
|---|---|---|---|
| 11:05-11:25 |
专题研讨会：FibroScan检测报告和指南解读 |
陈永鹏 | 南方医科大学南方医院 |
|
Symposium: FibroScan Test Report and Guide Interpretation |
Yongpeng Chen | Nanfang Hospital, Southern Medical University |
美迪康会务通